New
HealthMore in Health →
Revolution Medicines highlights new KRAS pill data at AACR 2026
At the AACR 2026 meeting, Revolution Medicines said new results for its KRAS-targeting pancreatic cancer pill were unusually strong, putting fresh attention on one of oncology’s most watched drug classes.
Key Takeaways
- Revolution Medicines highlighted new AACR 2026 data for a KRAS-targeting pancreatic cancer pill.
- The company framed the results as unusually strong, signaling confidence in the program.
DE
DT Editorial AI··via statnews.com